Illumina, Inc. $ILMN Stock Holdings Lessened by Westmount Partners LLC

Westmount Partners LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 35.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,726 shares of the life sciences company’s stock after selling 12,393 shares during the quarter. Illumina makes up approximately 0.9% of Westmount Partners LLC’s portfolio, making the stock its 20th largest position. Westmount Partners LLC’s holdings in Illumina were worth $3,996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Elyxium Wealth LLC purchased a new stake in Illumina in the 4th quarter worth approximately $25,000. Creative Capital Management Investments LLC grew its holdings in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the fourth quarter worth $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the fourth quarter worth $26,000. Finally, Activest Wealth Management raised its holdings in shares of Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 215 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ILMN shares. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Citigroup boosted their price target on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday. Piper Sandler restated an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday. Finally, Stifel Nicolaus raised their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $188.40.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina from “hold” to “strong buy,” citing favorable momentum characteristics. The company has also benefited from strong clinical momentum and continued leadership in genomic sequencing. Why Illumina Is a Strong Momentum Stock
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating, while TD Cowen maintained its “hold” rating. The mixed views indicate some analysts remain constructive on Illumina’s longer-term opportunity despite near-term concerns. Piper Sandler Reiterates Overweight Rating
• Neutral Sentiment: Illumina’s recent earnings showed revenue growth and an EPS beat, but investors remain focused on the sustainability of demand and whether growth can justify the stock’s elevated valuation following its strong 52-week advance.
• Negative Sentiment: Director Keith A. Meister sold approximately 741,000 Illumina shares across August 4 and 5 for a combined value of about $148.2 million, reducing his holdings by roughly 28% over the two transactions. Although he still owns more than 2 million shares, the large sales may weigh on investor sentiment. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated a “sell” rating and a $140 price target, arguing that a one-time consumables benefit is masking weak underlying demand. The target is substantially below recent trading levels, reinforcing concerns about near-term operating momentum. Bank of America Maintains Sell Rating on Illumina

Insider Buying and Selling

In related news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,744,811 shares of company stock worth $303,897,291 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Trading Down 3.1%

Illumina stock opened at $193.72 on Friday. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The company’s fifty day moving average price is $180.63 and its two-hundred day moving average price is $148.77. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market capitalization of $29.25 billion, a price-to-earnings ratio of 36.14, a PEG ratio of 2.81 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.